Related Experiment Video
Updated: Sep 1, 2025

Intraportal Transplantation of Pancreatic Islets in Mouse Model
Published on: May 5, 2018
Post-transplant diabetes mellitus following heart transplantation
Joshua D Newman1, Kelly H Schlendorf1, Zachary L Cox2
1Division of Cardiology, Section of Heart Failure and Cardiac Transplantation, Vanderbilt University Medical Center, Nashville, Tennessee.
Insights
Post-transplant diabetes mellitus (PTDM) affects over 20% of heart transplant recipients, often within the first year. PTDM increases infection, kidney failure, and mortality risks, necessitating tailored management strategies.
Area of Science:
- Cardiology
- Endocrinology
- Transplantation
Background:
- Post-transplant diabetes mellitus (PTDM) is a frequent complication after heart transplantation, affecting over 20% of patients.
- PTDM significantly elevates risks for post-operative infections, renal failure, and mortality, impacting long-term patient outcomes.
Approach:
- This review synthesizes current knowledge on PTDM definitions, incidence, and unique risk factors.
- It examines the pathophysiology, emphasizing the role of immunosuppressive medications in hyperglycemia.
- The review discusses emerging therapeutic options and pharmacologic considerations for PTDM management.
Key Points:
- PTDM presents distinct risk factors and pathophysiological mechanisms compared to pre-transplant diabetes.
- Immunosuppressive agents are critical contributors to PTDM development.
- Novel antihyperglycemic agents show promise in addressing PTDM.
Conclusions:
- Effective PTDM management is crucial for improving heart transplant recipient survival and quality of life.
- Further research is needed to optimize treatment strategies and understand long-term PTDM trajectories.
Abstract:
Post-transplant diabetes mellitus (PTDM) is common following heart transplant, impacting greater than 20% of patients with most cases occurring in the first year after transplant. PTDM is associated with multiple negative sequelae including increased post-operative infections, a higher rate of renal failure, and increased mortality. Compared with pre-transplant diabetes mellitus, PTDM has several unique risk factors and immunosuppressive medications play an important role in disease pathophysiology. Newer treatments for hyperglycemia, including glucagon like peptide-1 receptor agonists and sodium glucose cotransporter-2 inhibitors, may counter the mechanisms of immunosuppression-related hyperglycemia making them an appealing treatment option for patients with PTDM. Here, we review the definitions, incidence, risk factors, pathophysiology, clinical outcomes, treatment options, pharmacologic considerations, and future directions in PTDM.
Related Concept Videos
Kidney Transplant I: Introduction
Diabetes Mellitus: Type 2 and Gestational
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Symptoms, Diagnosis, and Complications

